Fourteen patients with severe cancer pain participated in a trial of methadone given in a fixed dose (10 mg) but at intervals selected by the patients themselves during the loading phase. The aim was to achieve rapid pain relief while avoiding the risk of toxicity from accumulation of methadone. As expected, the dosage intervals increased gradually over the first few days of treatment, the daily dose decreasing from 30-80 mg on the first day to 10-40 mg at the end of the week. Plasma concentrations of methadone varied sevenfold after four to five days (0 24 to 1-75 tmol/l; 7-4 to 54-2 ug/100 ml). Eleven patients reported complete or almost complete pain relief and elected to continue with methadone after the study. In no case was treatment withdrawn because of intoxication.
Introduction
In single doses methadone is reportedly a potent but fairly shortacting (four to six hours) narcotic analgesic.1 2 For severe chronic pain repeated doses-say, every six to eight hours-may, however, lead to accumulation of methadone with attendant toxicity.3 4The most likely reason for these findings is that during single-dose studies patients obtain pain relief only during short absorption-distribution phases. Tissue concentrations in the true elimination phase after the first dose are insufficient for analgesia. The elimination half life of methadone is 13-58 hours.5 Hence repeated dosing at fixed intervals-for example, thrice or four times daily-may lead to accumulation and toxicity.
These considerations of the pharmacokinetics of methadone and the need for a safe and more efficacious regimen for chronic severe pain in cancer led us to develop a protocol with a fixed dose but flexible and patient-controlled dosage intervals. We have evaluated this protocol in 14 patients and report here the results.
Patients and methods
We studied 14 patients (seven men and seven women) with incurable cancer (see table) . The study was performed in the departments of surgery and gynaecology of a general hospital (cases 1-6) and in a university department of oncology (cases 7-14). All patients had severe pain and had been treated with narcotic analgesics other than methadone. They had been admitted to hospital for diagnostic procedures and adjuvant care, including treatment of pain. Three patients (cases 7, 12, and 13) were given palliative irradiation therapy. The patients were informed about the purpose and design of the study and their consent obtained.
Design Analytical method-The plasma concentration of methadone was determined by mass fragmentography8 with the following modifications. A 2 ml sample was analysed; extraction was made with N-hexane after adding 2 ml 0-05M NaOH. The analogue 2-dimethylamino-4, 4-diphenyl-5-octanonehydrochloride was used as internal standard. Gas chromatographic separation was accomplished with a 1 m silanised glass column packed with 3% SP-2250-DB on 100-120 mesh Supelcoport. The lower limit of detection with the method was 30 nmol/l (0 9 Xug/100 ml). The coefficient of variation was 5-5o at 40 nmol/l (1 2 ,tg/100 ml; n= 10).
Results

DOSE REQUIREMENTS
During the first day the methadone dose varied between 30 and 100 mg in all patients. During the first week the dose requirement decreased successively to a mean of 21-5 mg (fig 1) . Accordingly the first dosage interval was short (three to seven hours), and increased to about 10 hours at the end of the week. After five to seven days the dosage intervals were set at eight or 12 hours, depending on the need of the patient. Individual doses varied between 10 and 15 mg and the daily dose between 10 and 40 mg.
PLASMA METHADONE CONCENTRATIONS
Plasma concentrations of methadone reached a plateau after two to three days. Considerable variations were found; fig 1 shows the concentrations before each dose in eight patients. After four to five days' treatment the concentrations ranged from 0 24 to 1 75 .tmol/l (7 4 to 54-2 ,ug/100 ml). Figure 2 shows a further example of the interindividual variation in the disposition of methadone. Despite a sevenfold difference in daily dose (per kg body weight) between the two patients (cases 5 and 6) the plasma concentrations were similar.
BRITISH MEDICAL JOURNAL VOLUME 282 7 MARCH 1981 (cases 2 and 4) considered all the effects advantageous. Of the remaining two patients, one (case 3) had rapidly progressive disease and was too ill to answer the questionnaire, and the other (case 6) did not continue treatment for the full week. This second patient, a 22-yearold woman with high tolerance for opiates ( Conversion: SI to traditional units-Methadone: 1 1emol/1I31 isg/ 100 ml.
EFFECTS
Eleven of the 14 patients reported complete or almost complete analgesic effect. Of the six patients studied in the departments of gynaecology and surgery, four (cases 1, 2, 4, and 5) completed the evaluation questionnaire after one week of treatment. All reported a positive effect (global assessment) and decreased pain intensity, and two reported improved mood, sleep, capacity for emotional contact, and decreased anxiety; three reported increased sedation. Two patients One patient (case 14) stopped methadone at the beginning of the second day after a total of 70 mg because of continuing pain. Interestingly, her plasma concentration was only 0-18 [±mol/l (5-6 [±g/100 ml). Subsequently she was treated with parenteral morphine (30-40 mg), which also had a suboptimal effect.
Treatment was therefore successful in 11 patients and failed in three. In two of the failures probably the dose was insufficient, owing to poor availability or rapid elimination, or both. The Methadone: 1 /xmol/l-31 pg/100 ml).
Discussion
The most important advantage of our patient-controlled methadone regimen was the rapid achievement of pain relief. The principle was similar to the patient-controlled schedule reported for post-operative pain.9 Those patients established constant and analgesic plasma concentrations by self-adjustment of the dose. Our study also shows that a self-adjusted dosage regimen may be employed without overdosing or serious side effects.
As expected, the dosage intervals increased with the longer duration of analgesia after repeated doses of methadone. A decrease of the required daily dose over the first few days was also reported by Valentine et al.2 On the sixth day the mean daily dose was only 21 5 mg.
The duration of analgesia after a single intramuscular dose of methadone in patients with cancer is reportedly four to six hours, which is similar to that of morphine.' The maximal effect occurs one to two hours after administration. On the other hand, the duration of other pharmacological effects of methadone have been reported to last longer. In healthy volunteers miosis appeared one to two hours after administration. The effect was maximal after three to four hours and lasted 31 to 47 hours.10 The time course for respiratory depression resembled that of miosis. The diversity of time courses for the different effects and side effects may be explained by different locations (compartments) where these effects are exerted. Possibly equilibrium between each of these locations and plasma is established at different times.
The use of methadone for severe pain in cancer has been accompanied by reports of intoxication. Several cases of serious and sometimes fatal respiratory depression associated with somnolence or coma have been described.3 In a study comparing methadone with diamorphine-cocaine, Twycross"l found that the mortality was significantly higher in the methadone group. In that study most of the patients were dosed every four to six hours with 5 to 20 mg. The rationale for the frequent administration (high daily doses) of methadone, which is also recommended by the manufacturer, was the short duration of analgesia observed after a single oral dose. Possibly the regimen was based on single-dose studies not taking into account the pharmacokinetics and pharmacodynamics of methadone.6 7 10 Frequent administration of 5-20 mg of methadone is therefore likely to lead to accumulation and toxicity in most patients.
The disposition of methadone is subject to large interindividual variation.7 The terminal half life ranges from 13 to 58 hours,5 and steady-state concentrations after a given dose may vary fourfold. In our patients there also appeared to be a pronounced interindividual variation in plasma concentration unrelated to dose. No clear-cut relation between the plasma concentrations and the analgesic effect could be established. This was, however, not expected, since the patients exhibited considerable.variation in pain intensity and tolerance to narcotic analgesics. Thus the attained plateau concentrations of methadone may give only an indication of the minimum effective plasma concentration.
Our results indicate that the following dose regimen of oral methadone may be used in patients with cancer: 10 mg methadone as required but not more than every four hours during the first three to five days, followed by a fixed dose every eight to 12 hours based on the patient's requirements. During the doseadjustment period the patient should be in hospital. Oral methadone given by this procedure affords safe and effective analgesia in most patients with cancer. It also allows the patient to spend more of his remaining life at home. MARIGOLDS are so plentiful in every garden, and so well known that they need no description. They flower all the Summer long, and sometimes in Winter, if it be mild.
It is an herb of the Sun, and under Leo. They strengthen the heart exceedingly, and are very expulsive, and a little less effectual in the smallpox and measles than saffron. The juice of Marigold leaves mixed with vinegar, and any hot swelling bathed with it, instantly gives ease, and assuages it. The flowers, either green or dried, are much used in possets, broths, and drink, as a comforter of the heart and spirits, and to expel any malignant or pestilential quality which might annoy them. A plaister made with the dry flowers in powder, hog's-grease, turpentine, and rosin, applied to the breast, strengthens and succours the heart infinitely in fevers, whether pestilential or not.
(Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)
